Orphazyme A/S ORPH

I’m
Buying more and averaging down no brainer

$ORPH come down to 6.

Everyone knows shorts covering hard. I guarantee the cocksuckers at fda was in on it and denied it to help them not lose a ton of money.

$ORPH holy shiet what just happened. Shiet just hit the fan or what.

Lol the shorts knew what’s up. They shorted at 70-25 now they cover and make bank. America= fuck the small guy and help the hedge fund billionaires

Albanian Bull why would you feel good about losing half your $AMC gains. The crazy thing is you haven’t even realized your amc gains. The market can turn on a drop of a dime.

Glad this is only .21% of my portfolio. I don’t risk much on shit that moves around like a tweeker. That’s right only .21%. If I lose it all will make it back with a real name like $$WISH

You can’t buy to much bio pharmaceutical stock. I only dipped my toe in with 200 shares at 16.25. If I lose $1200 oh well I cut the lose and use as tax deduction. Bio stocks are the biggest scams ever

$ORPH Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC).

The FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale (NPCCSS) and, in particular, the swallow domain. Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA.

Right off their website people!!